Biogen’s Alzheimer’s drug is unlikely to get EU approval.
Pharmaceutical manufacturer Biogen said on Wednesday The latest setback for a controversial drug since it was approved in the United States in June, when a drug review panel in the European Union said the new Alzheimer’s drug is unlikely to be approved there. Biogen said a committee of experts advising the European Medicines Agency issued …
Continue reading “Biogen’s Alzheimer’s drug is unlikely to get EU approval.”